Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
Amphastar Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.10, Amphastar Pharmaceuticals, Inc. trades at 12.9x trailing earnings, 1.7x sales and 1.5x book value, with an EV/EBITDA of 7.9. Over the last twelve months it generated about $750M of revenue and $96M of net income. It runs a gross margin of 46.8%, an operating margin of 18.7% and a net margin of 13.3%. It shows return on equity of 12.6%, return on invested capital of 6.9% and a free cash flow yield of 11.2%. On the balance sheet: a debt-to-equity ratio of 0.85 and a current ratio of 3.32. Over the past 52 weeks the share price ranged from $16.65 to $31.00, with a beta of 0.94.
Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 3 Buy, 8 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.